Latest Schedule 13G passive stakes

Karpus Management, Inc. has filed a Schedule 13G reporting an 8.54% beneficial ownership stake in Quartzsea Acquisition Corp.

Karpus Management, Inc. has filed an amended Schedule 13G, reporting a 1.82% beneficial ownership stake in Legato Merger Corp. III.

Karpus Management, Inc. reports 0% beneficial ownership in GP-Act III Acquisition Corp., indicating a full divestment of its previously held stake.

Karpus Management, Inc. has filed an amendment to its Schedule 13G, reporting a 0.05% beneficial ownership stake in Flag Ship Acquisition Corp.

Nicholas John Swenson and affiliated entities have filed a Schedule 13G reporting a 6.36% beneficial ownership stake in Park Dental Partners, Inc.

ARK Investment Management and Catherine Wood have disclosed a reduction in their beneficial ownership of 908 Devices Inc. to 4.94%.

Massachusetts Financial Services Company has reported a 6% beneficial ownership stake in QIAGEN N.V. as of May 29, 2026.

Prudential Financial, Inc. has filed a Schedule 13G reporting an 11.4% beneficial ownership stake in Cabaletta Bio, Inc.

Prudential Financial, Inc. has filed a Schedule 13G reporting an 11.4% beneficial ownership stake in Cabaletta Bio, Inc.

Investment adviser PRIMECAP Management Co. has reported a 10.46% beneficial ownership stake in American Airlines Group Inc.

Janus Henderson Group plc has filed a Schedule 13G reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock.

Janus Henderson Group plc has filed a Schedule 13G reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock.

Janus Henderson Group plc has reported a 13% beneficial ownership stake in Immix Biopharma, Inc. through its various investment management subsidiaries.

Janus Henderson Group plc has reported a 13% beneficial ownership stake in Immix Biopharma, Inc. through its various investment management subsidiaries.

Investment firm Dodge & Cox reports a 12.1% beneficial ownership stake in TransUnion common stock.

Elliot Weinberger filed a Schedule 13G indicating zero beneficial ownership of Hub Cyber Security Ltd. ordinary shares.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting a 6.6% beneficial ownership stake in Karyopharm Therapeutics Inc.

T. Rowe Price Associates, Inc. filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.2% in Tenax Therapeutics, Inc.

T. Rowe Price Associates, Inc. filed an amendment to its Schedule 13G, reporting a reduction in its beneficial ownership of Upwork Inc. common stock to 0.2%.

Invesco Ltd. has filed a Schedule 13G reporting beneficial ownership of 20.6% of the Invesco Bloomberg Enhanced Fallen Angels ETF.

Invesco Ltd. has filed a Schedule 13G reporting a 15% beneficial ownership stake in Canaan Inc. American Depository Receipts.

Invesco Ltd. has filed a Schedule 13G reporting a 15% beneficial ownership stake in Canaan Inc. American Depository Receipts.

Investment firm Domicilium Capital Partners and affiliates report a 4.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

Sit Investment Associates, Inc. and Sit Fixed Income Advisors II, LLC have filed an amendment reporting a 0% beneficial ownership stake in NXG Cushing Midstream Energy Fund.

FMR LLC and Abigail P. Johnson have reported a 46.6% beneficial ownership stake in Cerebras Systems Inc. Class A Common Stock.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting a 10.3% beneficial ownership stake in Baxter International Inc.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting beneficial ownership of 11.3% of Biogen Inc. common stock.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting beneficial ownership of 10.4% of Rambus Inc common stock.

FMR LLC and Abigail P. Johnson have reported a 10.1% beneficial ownership stake in Veracyte Inc as of May 29, 2026.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting a 6.1% beneficial ownership stake in Avalo Therapeutics Inc.